Answers are grounded in this paper and cite their sources.
Systematic review evaluates heart rate variability as a biomarker in breast cancer, highlighting the vagus nerve's role in inflammation and prognosis.
Heart rate variability (HRV), a non-invasive measure of autonomic nervous system (ANS) function reflecting vagus nerve activity, is a promising biomarker in breast cancer (BC) management. This PRISMA-guided systematic review evaluates HRV electrophysiologic data from 5-minute vs. 24-hour ECG recordings in BC diagnosis and therapy follow-up, emphasizing the vagus nerve’s role in inflammation and tumor progression. Completing a search of PubMed, Scopus, Web of Science, and Embase (2009–2025), 16 studies (n=3,412 participants) were included. Lower HRV metrics (e.g., SDNN <50 ms, RMSSD <20 ms predicted relapse) correlated with advanced BC stages, elevated carcinoembryonic antigen (CEA), and poorer prognosis (HR=0.62, 95% CI: 0.48–0.79). Chemotherapy-induced HRV reductions (e.g., SDNN decrease by 20%) predicted cardiotoxicity, while vagus nerve stimulation (VNS) improved HRV and reduced inflammation. HRV showed diagnostic sensitivity up to 80% with biomarkers. A narrative synthesis was conducted due to methodological heterogeneity; meta-analysis was not feasible due to significant methodological heterogeneity across studies. HRV and vagal interventions hold transformative potential, necessitating standardized protocols and larger studies.
No takes yet. Share an insight, caveat, or question.
Koutsojannis et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: